Skip to main content
Toggle navigation
Login
Search
Home
Program Book
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Like
Tweet
Olivia Adams
Stemline 1
Poster(s):
(328) Elacestrant (ELA) vs standard-of-care (SOC) in ER+/HER2- advanced (adv) or metastatic breast cancer (mBC) with ESR1 mutation (ESR1-mut): key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial
Wednesday, April 3, 2024
5:00 PM – 7:00 PM
ET
(329) Estimating the Direct and Indirect Resource Burden of Treatment Management with Current Standard of Care or Elacestrant for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population-Level Provider Model
Wednesday, April 3, 2024
5:00 PM – 7:00 PM
ET